secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2026-10-13T20:32:09+00:00
Accession:  0001628171-26-000004
Event type: debt
Sentiment:  positive
Materiality: 0.60
Item codes: 2.03, 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Revolution Medicines draws $250M Tranche A loan after FDA approves RASONQUE for pancreatic cancer
--------------------------------------------------------------------------------

- Tranche A Loan of $250.0M funded Oct 8, 2026, triggered by FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy.
- Interest at 3-month Term SOFR, floor of 3.50%, plus 5.75%, payable quarterly in arrears; interest-only with principal due Oct 8, 2032.
- Company paid Royalty Pharma a $5.0M draw fee; up to $500.0M more available under the $750.0M senior secured facility subject to milestones.
- Prepayment terms: make-whole plus 3.0% premium before the 2nd anniversary, 3.0% before the 3rd, and 1.0% thereafter.
- Company elected not to deliver a Tranche 3 Notice by the Oct 10, 2026 deadline, forgoing up to $250.0M and selling no incremental revenue participation right.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000162817126000004/0001628171-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000162817126000004/rvmd-20261008.htm
  HTML page:      https://secwatch.observer/filing/0001628171-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer